January 5, 2016 10:23am
Covering composition and methods related to its LADD and GVAX immunotherapy technologies
Patent 9,198,960 claims methods for enhancing an immune response to mesothelin by administering first a "prime" dose of an inactivated tumor cell containing a nucleic acid that encodes granulocyte macrophage-colony stimulation factor (GM-CSF) followed by a "boost" dose of an immunotherapy. The nominal expiration date for this patent is July 17, 2027, subject to any extensions that may be available.
Patent 9,200,057, which is jointly owned with Providence Health & Services. The nominal expiration date for this patent is November 17, 2031, subject to any extensions that may be available.
The Bottom Line: These two patents expand its claims associated with therapeutic approaches and extend patent coverage into 2031
ADRO is UP +$0.15 on small volume to $26.79